Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

157.70
-3.7700-2.33%
Post-market: 158.010.3100+0.20%19:58 EDT
Volume:3.38M
Turnover:536.85M
Market Cap:244.59B
PE:23.61
High:161.33
Open:160.77
Low:157.54
Close:161.47
52wk High:212.71
52wk Low:153.41
Shares:1.55B
Float Shares:1.50B
Volume Ratio:1.34
T/O Rate:0.23%
Dividend:3.16
Dividend Rate:2.01%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.02%
PB:4.86
PE(LYR):24.11

Loading ...

AstraZeneca's Long-Term Outlook Could Look Safer After Next Year

Dow Jones
·
Sep 16

AstraZeneca Can Meet 2030 Target Even if Lung-Cancer Trial Fails

Dow Jones
·
Sep 16

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Sep 16

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16

AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg

TIPRANKS
·
Sep 16

Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating

MT Newswires Live
·
Sep 15

AstraZeneca's Portfolio Diversity Bodes Well

Dow Jones
·
Sep 15

AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank

TIPRANKS
·
Sep 15

Berenberg Bank Remains a Buy on AstraZeneca (AZN)

TIPRANKS
·
Sep 15

RBC Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Sep 15

Top Midday Decliners

MT Newswires Live
·
Sep 15

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Dow Jones
·
Sep 15

AstraZeneca Can Overcome Recent Trial Setbacks

Dow Jones
·
Sep 14

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

AstraZeneca, Daiichi Drug Has Good Lung-Cancer Data, but Competition Awaits

Dow Jones
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

AstraZeneca reports results from DESTINY-Lung04 trial

TIPRANKS
·
Sep 14

AstraZeneca reports updated exploratory results from ADAURA trial

TIPRANKS
·
Sep 14

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Sep 14

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14